[PET-CT for neuroendocrine tumors and nuclear medicine therapy options].
Identifieur interne : 001B58 ( Main/Exploration ); précédent : 001B57; suivant : 001B59[PET-CT for neuroendocrine tumors and nuclear medicine therapy options].
Auteurs : RBID : pubmed:19296068English descriptors
- KwdEn :
- Digestive System Neoplasms (pathology), Digestive System Neoplasms (radionuclide imaging), Digestive System Neoplasms (radiotherapy), Humans, Image Processing, Computer-Assisted, Liver Neoplasms (pathology), Liver Neoplasms (radionuclide imaging), Liver Neoplasms (radiotherapy), Liver Neoplasms (secondary), Neoplasm Staging, Neuroendocrine Tumors (pathology), Neuroendocrine Tumors (radionuclide imaging), Neuroendocrine Tumors (radiotherapy), Positron-Emission Tomography, Prognosis, Radiation Dosage, Radioisotopes (adverse effects), Radioisotopes (diagnostic use), Sensitivity and Specificity, Somatostatin (analogs & derivatives), Somatostatin (diagnostic use), Somatostatin (therapeutic use), Tomography, X-Ray Computed, Whole Body Imaging.
- MESH :
- chemical , adverse effects : Radioisotopes.
- chemical , analogs & derivatives : Somatostatin.
- chemical , diagnostic use : Radioisotopes, Somatostatin.
- pathology : Digestive System Neoplasms, Liver Neoplasms, Neuroendocrine Tumors.
- radionuclide imaging : Digestive System Neoplasms, Liver Neoplasms, Neuroendocrine Tumors.
- radiotherapy : Digestive System Neoplasms, Liver Neoplasms, Neuroendocrine Tumors.
- secondary : Liver Neoplasms.
- chemical , therapeutic use : Somatostatin.
- Humans, Image Processing, Computer-Assisted, Neoplasm Staging, Positron-Emission Tomography, Prognosis, Radiation Dosage, Sensitivity and Specificity, Tomography, X-Ray Computed, Whole Body Imaging.
Abstract
Neuroendocrine tumors (NET) are defined by biochemical characteristics and structures which can be specifically addressed by radioligands for diagnostic imaging as well as radionuclide therapy in nuclear medicine. Somatostatin receptor imaging has been shown to be an important part of the diagnostic process in the management of NET for a long time. In recent years a number of tracers enabling PET-based imaging of somatostatin receptors and amine precursor uptake have been developed. By combining the specific functional information of the PET signal with anatomical information by CT imaging using PET-CT hybrid scanners, primary tumors and metastases can be detected with high resolution and high sensitivity. Compared with conventional indium-111 octreotide scintigraphy PET-CT has a higher resolution and also a lower radiation exposure. In addition, quantification of the tracer uptake allows therapy monitoring. By labelling with therapeutic beta-emitters, such as lutetium-177 or yttrium-90, a systemic internal radiotherapy with somotostatin analogues (peptide radionuclide radiation therapy, PRRT) can be provided as a therapeutic option for patients with unresectable and metastasized neuroendocrine tumors.
DOI: 10.1007/s00117-008-1784-9
PubMed: 19296068
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">[PET-CT for neuroendocrine tumors and nuclear medicine therapy options].</title><author><name sortKey="Scheidhauer, K" uniqKey="Scheidhauer K">K Scheidhauer</name><affiliation wicri:level="3"><nlm:affiliation>Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technische Universität München, München, Deutschland. k.scheidhauer@lrz.tum.de</nlm:affiliation><country xml:lang="fr">Allemagne</country><wicri:regionArea>Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technische Universität München, München</wicri:regionArea><placeName><region type="land" nuts="1">Bavière</region><region type="district" nuts="2">District de Haute-Bavière</region><settlement type="city">Munich</settlement></placeName></affiliation></author><author><name sortKey="Miederer, M" uniqKey="Miederer M">M Miederer</name></author><author><name sortKey="Gaertner, F C" uniqKey="Gaertner F">F C Gaertner</name></author></titleStmt><publicationStmt><date when="2009">2009</date><idno type="doi">10.1007/s00117-008-1784-9</idno><idno type="RBID">pubmed:19296068</idno><idno type="pmid">19296068</idno><idno type="wicri:Area/Main/Corpus">001F71</idno><idno type="wicri:Area/Main/Curation">001F71</idno><idno type="wicri:Area/Main/Exploration">001B58</idno></publicationStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Digestive System Neoplasms (pathology)</term><term>Digestive System Neoplasms (radionuclide imaging)</term><term>Digestive System Neoplasms (radiotherapy)</term><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Liver Neoplasms (pathology)</term><term>Liver Neoplasms (radionuclide imaging)</term><term>Liver Neoplasms (radiotherapy)</term><term>Liver Neoplasms (secondary)</term><term>Neoplasm Staging</term><term>Neuroendocrine Tumors (pathology)</term><term>Neuroendocrine Tumors (radionuclide imaging)</term><term>Neuroendocrine Tumors (radiotherapy)</term><term>Positron-Emission Tomography</term><term>Prognosis</term><term>Radiation Dosage</term><term>Radioisotopes (adverse effects)</term><term>Radioisotopes (diagnostic use)</term><term>Sensitivity and Specificity</term><term>Somatostatin (analogs & derivatives)</term><term>Somatostatin (diagnostic use)</term><term>Somatostatin (therapeutic use)</term><term>Tomography, X-Ray Computed</term><term>Whole Body Imaging</term></keywords><keywords scheme="MESH" type="chemical" qualifier="adverse effects" xml:lang="en"><term>Radioisotopes</term></keywords><keywords scheme="MESH" type="chemical" qualifier="analogs & derivatives" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" type="chemical" qualifier="diagnostic use" xml:lang="en"><term>Radioisotopes</term><term>Somatostatin</term></keywords><keywords scheme="MESH" qualifier="pathology" xml:lang="en"><term>Digestive System Neoplasms</term><term>Liver Neoplasms</term><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="radionuclide imaging" xml:lang="en"><term>Digestive System Neoplasms</term><term>Liver Neoplasms</term><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="radiotherapy" xml:lang="en"><term>Digestive System Neoplasms</term><term>Liver Neoplasms</term><term>Neuroendocrine Tumors</term></keywords><keywords scheme="MESH" qualifier="secondary" xml:lang="en"><term>Liver Neoplasms</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Somatostatin</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Humans</term><term>Image Processing, Computer-Assisted</term><term>Neoplasm Staging</term><term>Positron-Emission Tomography</term><term>Prognosis</term><term>Radiation Dosage</term><term>Sensitivity and Specificity</term><term>Tomography, X-Ray Computed</term><term>Whole Body Imaging</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Neuroendocrine tumors (NET) are defined by biochemical characteristics and structures which can be specifically addressed by radioligands for diagnostic imaging as well as radionuclide therapy in nuclear medicine. Somatostatin receptor imaging has been shown to be an important part of the diagnostic process in the management of NET for a long time. In recent years a number of tracers enabling PET-based imaging of somatostatin receptors and amine precursor uptake have been developed. By combining the specific functional information of the PET signal with anatomical information by CT imaging using PET-CT hybrid scanners, primary tumors and metastases can be detected with high resolution and high sensitivity. Compared with conventional indium-111 octreotide scintigraphy PET-CT has a higher resolution and also a lower radiation exposure. In addition, quantification of the tracer uptake allows therapy monitoring. By labelling with therapeutic beta-emitters, such as lutetium-177 or yttrium-90, a systemic internal radiotherapy with somotostatin analogues (peptide radionuclide radiation therapy, PRRT) can be provided as a therapeutic option for patients with unresectable and metastasized neuroendocrine tumors.</div></front></TEI><pubmed><MedlineCitation Owner="NLM" Status="MEDLINE"><PMID Version="1">19296068</PMID><DateCreated><Year>2009</Year><Month>03</Month><Day>19</Day></DateCreated><DateCompleted><Year>2009</Year><Month>06</Month><Day>17</Day></DateCompleted><DateRevised><Year>2009</Year><Month>07</Month><Day>13</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1432-2102</ISSN><JournalIssue CitedMedium="Internet"><Volume>49</Volume><Issue>3</Issue><PubDate><Year>2009</Year><Month>Mar</Month></PubDate></JournalIssue><Title>Der Radiologe</Title><ISOAbbreviation>Radiologe</ISOAbbreviation></Journal><ArticleTitle>[PET-CT for neuroendocrine tumors and nuclear medicine therapy options].</ArticleTitle><Pagination><MedlinePgn>217-23</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1007/s00117-008-1784-9</ELocationID><Abstract><AbstractText>Neuroendocrine tumors (NET) are defined by biochemical characteristics and structures which can be specifically addressed by radioligands for diagnostic imaging as well as radionuclide therapy in nuclear medicine. Somatostatin receptor imaging has been shown to be an important part of the diagnostic process in the management of NET for a long time. In recent years a number of tracers enabling PET-based imaging of somatostatin receptors and amine precursor uptake have been developed. By combining the specific functional information of the PET signal with anatomical information by CT imaging using PET-CT hybrid scanners, primary tumors and metastases can be detected with high resolution and high sensitivity. Compared with conventional indium-111 octreotide scintigraphy PET-CT has a higher resolution and also a lower radiation exposure. In addition, quantification of the tracer uptake allows therapy monitoring. By labelling with therapeutic beta-emitters, such as lutetium-177 or yttrium-90, a systemic internal radiotherapy with somotostatin analogues (peptide radionuclide radiation therapy, PRRT) can be provided as a therapeutic option for patients with unresectable and metastasized neuroendocrine tumors.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Scheidhauer</LastName><ForeName>K</ForeName><Initials>K</Initials><Affiliation>Nuklearmedizinische Klinik und Poliklinik, Klinikum rechts der Isar der Technische Universität München, München, Deutschland. k.scheidhauer@lrz.tum.de</Affiliation></Author><Author ValidYN="Y"><LastName>Miederer</LastName><ForeName>M</ForeName><Initials>M</Initials></Author><Author ValidYN="Y"><LastName>Gaertner</LastName><ForeName>F C</ForeName><Initials>FC</Initials></Author></AuthorList><Language>ger</Language><PublicationTypeList><PublicationType>English Abstract</PublicationType><PublicationType>Journal Article</PublicationType><PublicationType>Review</PublicationType></PublicationTypeList><VernacularTitle>PET-CT bei neuroendokrinen Tumoren und nuklearmedizinische Therapiemöglichkeiten.</VernacularTitle></Article><MedlineJournalInfo><Country>Germany</Country><MedlineTA>Radiologe</MedlineTA><NlmUniqueID>0401257</NlmUniqueID><ISSNLinking>0033-832X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance>Radioisotopes</NameOfSubstance></Chemical><Chemical><RegistryNumber>51110-01-1</RegistryNumber><NameOfSubstance>Somatostatin</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName MajorTopicYN="N">Digestive System Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Image Processing, Computer-Assisted</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Liver Neoplasms</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="N">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName><QualifierName MajorTopicYN="N">secondary</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Neuroendocrine Tumors</DescriptorName><QualifierName MajorTopicYN="N">pathology</QualifierName><QualifierName MajorTopicYN="Y">radionuclide imaging</QualifierName><QualifierName MajorTopicYN="N">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Positron-Emission Tomography</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Prognosis</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radiation Dosage</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Radioisotopes</DescriptorName><QualifierName MajorTopicYN="N">adverse effects</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Sensitivity and Specificity</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Somatostatin</DescriptorName><QualifierName MajorTopicYN="N">analogs & derivatives</QualifierName><QualifierName MajorTopicYN="N">diagnostic use</QualifierName><QualifierName MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="Y">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName MajorTopicYN="N">Whole Body Imaging</DescriptorName></MeshHeading></MeshHeadingList><NumberOfReferences>16</NumberOfReferences></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2009</Year><Month>3</Month><Day>20</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2009</Year><Month>6</Month><Day>18</Day><Hour>9</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="doi">10.1007/s00117-008-1784-9</ArticleId><ArticleId IdType="pubmed">19296068</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=IndiumV2/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001B58 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001B58 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= *** parameter Area/wikiCode missing ***
|area= IndiumV2
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:19296068
|texte= [PET-CT for neuroendocrine tumors and nuclear medicine therapy options].
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:19296068" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a IndiumV2
| This area was generated with Dilib version V0.5.76. |  |